Butyrate Ameliorates Graves’ Orbitopathy Through Regulating Orbital Fibroblast Phenotypes and Gut Microbiota
Butyrate ameliorates several of the symptoms of GO, lowering GO orbital fibroblast viability, adipogenesis, and TGF-β1-induced fibrosis without damaging normal fibroblasts. Butyrate normalizes thyroid function in a GO mouse model, improves histopathological alterations, and transforms gut microbiota populations, proving its potential in treating GO through the gut-thyroid axis.
Authors
- Pingbo Ouyang (ORCID: https://orcid.org/0000-0003-3321-3478)
- Boding Tong
- Xin Qi (ORCID: https://orcid.org/0000-0002-0426-4156)
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Qi Jia (ORCID: https://orcid.org/0000-0002-8124-8432)
- Yun Li (ORCID: https://orcid.org/0000-0003-0486-9259)
- Jiamin Cao (ORCID: https://orcid.org/0000-0003-2498-3454)
- Lujue Wang
Institutions
- Central South University (CN)
- Second Xiangya Hospital of Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- Investigative Ophthalmology & Visual Science
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1167/iovs.66.3.5
- Citations
- 7
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 10.30